ArticleClinical cancer research : an official journal of the American Association for Cancer Research2018
Rates of
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 36 citations in OpenAlex.
- Does the ERBB/EGF Signaling Network Serve as a Nexus for Oncogenic Signals in Uveal Melanoma?Biomolecules · 2026Review
- Preclinical development and selection of nanobody-based CAR-T cells targeting HER2-positive solid tumors.Molecular therapy. Oncology · 2025Article
- Genomic profiling and personalized treatment strategies for skin malignancies: findings from the center for cancer genomics and advanced therapeutics database.International journal of clinical oncology · 2025Review
- ERBB2/ERBB3-mutated S100/SOX10-positive uterine sarcoma: something new.Virchows Archiv : an international journal of pathology · 2025Article
- Receptor tyrosine kinase inhibition leads to regression of acral melanoma by targeting the tumor microenvironment.Journal of experimental & clinical cancer research : CR · 2024Article
- Genomic landscape of cutaneous, acral, mucosal, and uveal melanoma in Japan: analysis of clinical comprehensive genomic profiling data.International journal of clinical oncology · 2024Article
- Expanding the landscape of oncogenic drivers and treatment options in acral and mucosal melanomas by targeted genomic profiling.International journal of cancer · 2024Article
- Genetic Characteristics of Cutaneous, Acral, and Mucosal Melanoma in Japan.Cancer medicine · 2024Article
- Expression of c-erb-B2 oncoprotein as a neoantigen strategy to repurpose anti-neu antibody therapy in a model of melanoma.Scientific reports · 2024Article
- Receptor tyrosine kinase inhibition leads to regression of acral melanoma by targeting the tumor microenvironment.bioRxiv : the preprint server for biology · 2024Article
- Transcriptional background effects on a tumor driver gene in different pigment cell types of medaka.Journal of experimental zoology. Part B, Molecular and developmental evolution · 2024Article
- Multidisciplinary approach and treatment of acral and mucosal melanoma.Frontiers in oncology · 2024Review
- Combinations of EGFR and MET inhibitors reduce proliferation and invasiveness of mucosal melanoma cells.Journal of cellular and molecular medicine · 2023Article
- A Tumor and Immune-Related Micro-RNA Signature Predicts Relapse-Free Survival of Melanoma Patients Treated with Ipilimumab.International journal of molecular sciences · 2023Article
- Genomic and tumour microenvironmental biomarkers of immune checkpoint inhibitor response in advanced Taiwanese melanoma.Clinical & translational immunology · 2023Article
- Management of Acral and Mucosal Melanoma: Medical Oncology Perspective.The oncologist · 2022Review
- Gene Identification and Potential Drug Therapy for Drug-Resistant Melanoma with Bioinformatics and Deep Learning Technology.Disease markers · 2022Article
- The clinicopathologic spectrum and genomic landscape of de-/trans-differentiated melanoma.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2021Article
- Cutaneous Melanoma Classification: The Importance of High-Throughput Genomic Technologies.Frontiers in oncology · 2021Review
- Innate-like NKp30Oncoimmunology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
purposePatients with PATIENTS AND
methodsAll patients with nonuveal melanoma (cutaneous, acral, mucosal, and unknown primary) whose tumors underwent multigene sequencing with MSK-IMPACT at Memorial Sloan Kettering Cancer Center (New York, NY) from 2014 to 2018 were reviewed for known or likely oncogenic somatic alterations in
resultsA patient with acral melanoma resistant to checkpoint inhibition was found to have
conclusions
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.